MARKET

PTCT

PTCT

PTC Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.48
-4.34
-9.90%
Closed 19:09 09/23 EDT
OPEN
42.10
PREV CLOSE
43.82
HIGH
42.10
LOW
37.97
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
70.82
52 WEEK LOW
36.38
MARKET CAP
2.79B
P/E (TTM)
-7.0209
1D
5D
1M
3M
1Y
5Y
PTC Therapeutics To Host Call To Discuss Results Of PTC518 Phase 1 Study For Huntington's Disease Program Thursday, Sept. 23, 2021 At 8 a.m. EDT
PTC Therapeutics, Inc. (NASDAQ:PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study. The new results include HTT mRNA and protein lowering, as well as
Benzinga · 3d ago
PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program
/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study. The new results include HTT mRNA and protein lowering, as well as PTC518 exposure levels in t...
PR Newswire - PRF · 3d ago
BRIEF-PTC Therapeutics Inc Data Show Translarna Delays Loss Of Ambulation By More Than Five Years
reuters.com · 3d ago
STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy
PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Translarna™ (ataluren) delays loss of ambulation by more than five years in boys with nonsense mutation Duchenne mus...
PR Newswire · 3d ago
PTC Therapeutics Says Translarna Therapy Delays Loss of Ambulation in Nonsense Mutation Duchenne Muscular Dystrophy
MT Newswires · 4d ago
Aadi Bioscience Appoints Emma Reeve to its Board of Directors
LOS ANGELES, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announce...
GlobeNewswire · 09/13 12:00
Phenylketonuria Drugs Market- Demand, Trends, Share,Global Demand Analysis and Opportunity Outlook 2029
Research Nester published a report titled  which delivers detailed overview of the global phenylketonuria drugs market in terms of market segmentation by drug type, route of administration, end users, and by region.
AmericaNewsHour · 09/08 06:26
PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program. The global STRIVE Awards program provides grants to non-profit organizations serving the Duchenne muscular dyst...
PR Newswire · 09/07 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTCT. Analyze the recent business situations of PTC Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PTCT stock price target is 56.80 with a high estimate of 75.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 278
Institutional Holdings: 76.56M
% Owned: 108.43%
Shares Outstanding: 70.60M
TypeInstitutionsShares
Increased
83
5.43M
New
16
608.78K
Decreased
48
3.86M
Sold Out
40
2.13M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
Michael Schmertzler
Chief Executive Officer/Director
Stuart Peltz
Chief Financial Officer
Emily Hill
Chief Operating Officer/Chief Technology Officer
Neil Almstead
Executive Vice President
Mark Boulding
Senior Vice President/Chief Accounting Officer
Christine Utter
Other
Matthew Klein
Other
Eric Pauwels
Independent Director
Allan Jacobson
Independent Director
Stephanie Okey
Independent Director
Emma Reeve
Independent Director
Mary Smith
Independent Director
David Southwell
Independent Director
Glenn Steele
Independent Director
Dawn Svoronos
Independent Director
Jerome Zeldis
No Data
  • All
  • Financials
  • Insiders
More
About PTCT
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company have a portfolio pipeline that includes commercial products as well as product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company have two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company have a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) and PTC923 for phenylketonuria (PKU) diseases.

Webull offers kinds of PTC Therapeutics, Inc. stock information, including NASDAQ:PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.